<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989310</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-PLAGH-BT-041</org_study_id>
    <nct_id>NCT03989310</nct_id>
  </id_info>
  <brief_title>An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase I/II, Open-label, One-arm, Single-center Study to Evaluate the Safety and Efficacy of the Pan-immunotherapy in Subjects With Local Advanced/Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The outcome of pancreatic cancer is extremely poor. NCCN guidelines recommend FOLFIRINOX or&#xD;
      modified-FOLFIRINOX as the first-line chemotherapeutic regimen, but the response rate is&#xD;
      unacceptably low. PD-1 blockade has been developed to a new class of cancer immunotherapy&#xD;
      that could restore an adequate immunosurveillance against the neoplasm and enhance&#xD;
      T-cell-mediated anticancer immune responses. Manganese has been confirmed to activate&#xD;
      antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies.&#xD;
      This one-arm, phase I/II study is designed to assess the safety and efficacy of Manganese&#xD;
      primed combined therapy of anti-PD-1 antibody and chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects with treatment-related adverse events (AEs)</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0. AEs were considered to be treatment-related if they had started or worsened within the interval from first study drug administration until the follow-up visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>12 months</time_frame>
    <description>DCR is defined as the proportion of subjects who achieved a stable disease (SD), partial response (PR) or complete response (CR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Object response rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>ORR is defined as the proportion of subjects who achieved a partial response (PR) or complete response (CR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>PFS time was measured from study entry to the first documentation of disease progression or death. Disease progression was determined per the RECIST V1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>OS time was measured from the study entry to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with laboratory test abnormalities</measure>
    <time_frame>12 months</time_frame>
    <description>The laboratory tests of serum cytokines and chemokines will be performed on day 1 and 3 of each cycle, and the abnormality will be determined by the investigator.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Manganese primed anti-PD-1 antibody plus nPG chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject received Manganese primed anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>anti-PD-1 antibody plus nPG chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject received anti-PD-1 antibody, nab-paclitaxel and gemcitabine every 3 weeks until achieving a second assessable stable disease or up to a maximum of 12 cycles. Treatment continued until progressive disease, development of unacceptable toxicity, or withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Manganese Chloride</intervention_name>
    <description>Administered by inhalation at 0.4mg/kg twice per week in a 3-week cycle</description>
    <arm_group_label>Manganese primed anti-PD-1 antibody plus nPG chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Administered intravenously, 200mg/d on day 1 and day 8 in a 3-week cycle</description>
    <arm_group_label>Manganese primed anti-PD-1 antibody plus nPG chemotherapy</arm_group_label>
    <arm_group_label>anti-PD-1 antibody plus nPG chemotherapy</arm_group_label>
    <other_name>Paclitaxel For Injection (Albumin Bound)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle</description>
    <arm_group_label>Manganese primed anti-PD-1 antibody plus nPG chemotherapy</arm_group_label>
    <arm_group_label>anti-PD-1 antibody plus nPG chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-PD-1 antibody</intervention_name>
    <description>Administered intravenously, 2-4mg/kg on day 2 in a 3-week cycle</description>
    <arm_group_label>Manganese primed anti-PD-1 antibody plus nPG chemotherapy</arm_group_label>
    <arm_group_label>anti-PD-1 antibody plus nPG chemotherapy</arm_group_label>
    <other_name>Anti-PD-1 monoclonal antibody; PD-1 inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must have histologically proven local advanced/metastatic pancreatic cancer&#xD;
&#xD;
          2. ≥ 18 years old.&#xD;
&#xD;
          3. Life expectancy of at least 6 months.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group performance status 0-2.&#xD;
&#xD;
          5. Subjects must have at least one measurable lesion ≥ 1 cm as defined by response&#xD;
             criteria.&#xD;
&#xD;
          6. Subjects with Anti-PD-1 antibody treatment history are eligible which must be&#xD;
             resistance.&#xD;
&#xD;
          7. Adequate organ function.&#xD;
&#xD;
          8. Participants of childbearing potential must be willing to use an adequate method of&#xD;
             contraception for the course of the study through 120 days after the last dose of&#xD;
             study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with any autoimmune disease or history of syndrome that requires&#xD;
             corticosteroids or immunosuppressive medications.&#xD;
&#xD;
          2. Serious uncontrolled medical disorders or active infections, pulmonary infection&#xD;
             especially.&#xD;
&#xD;
          3. Prior organ allograft.&#xD;
&#xD;
          4. Women who are pregnant or breastfeeding.&#xD;
&#xD;
          5. Women with a positive pregnancy test on enrollment or prior to investigational product&#xD;
             administration.&#xD;
&#xD;
          6. Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (eg, infectious disease) illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weidong Han</last_name>
    <phone>01066937463</phone>
    <email>hanwdrsw@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biotherapeutic Department of Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong Han, M.D</last_name>
      <phone>+86-10-66937463</phone>
      <email>hanwdrsw@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Qingming Yang, M.D</last_name>
      <phone>+86-10-55499341</phone>
      <email>yangqm301@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Weidong Han, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qian Mei, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qingming Yang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meixia Chen, M.S.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan Zhang, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaichao Feng, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yang Liu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiejie Liu, B.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiang Li, B.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liang Dong, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 15, 2019</study_first_submitted>
  <study_first_submitted_qc>June 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>December 20, 2020</last_update_submitted>
  <last_update_submitted_qc>December 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Han weidong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>local advanced</keyword>
  <keyword>metastatic</keyword>
  <keyword>anti-PD-1 antibody</keyword>
  <keyword>Manganese</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Manganese</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

